Kyndryl Q4 Earnings Miss Deepens Turnaround Doubts

What happened

Kyndryl reported Q4 earnings of $0.18 per share, missing the consensus estimate of $0.43 and declining from $0.52 a year ago, continuing a pattern of revenue shortfalls despite margin progress. The miss reinforces market skepticism about management's ability to convert a record $18.2B signings backlog into sustainable top-line growth, as H1 FY26 constant-currency revenue remained negative. While cost actions and mix shift have lifted adjusted EBITDA margins into the mid-teens, cash generation remains lumpy and H1 operating cash flow was only $22M. The master report's base case assumes 1–2% revenue growth and ~$550M FCF by FY27, but this miss delays confidence in a near-term inflection. However, the stock already trades at ~11x trailing EPS and ~5.5x EV/EBITDA, embedding substantial execution risk that could be rewarded if FY26 guidance is met.

Implication

If Kyndryl delivers on FY26 guidance of +1% constant-currency growth and ~$550M FCF, the current depressed valuation (~11x P/E) offers material upside as a turnaround play; monitor signings conversion and cash flow in upcoming quarters.

Thesis delta

The Q4 miss reinforces the bear case that revenue inflection is delayed and execution risk is higher than previously assumed. While the long-term thesis still hinges on backlog conversion and margin expansion, near-term confidence in hitting FY26 guidance declines, warranting a more cautious stance until H2 results improve.